Key Highlights
- Vivo Infusion acquires Infusion Associates.
- Expansion to nearly 80 ambulatory infusion centers in 15 states.
- Infusion Associates’ unique operating model and clinical trials division.
- InTandem Capital Partners raises $150 million for continued growth.
- Continued Midwest expansion with new de novo center build-outs.
Source: Business Wire
Notable Quotes
- “We are thrilled to welcome the Infusion Associates team to the Vivo family. Infusion Associates brings several unique capabilities to Vivo’s growing business which will continue to strengthen our relationships with our patients, payors and pharma partners. We are delighted to partner with the entire team.” — Chris Reef, Chief Executive Officer at Vivo Infusion
- “I am excited to join the Vivo mission. We look forward to bringing these two great companies together and serving more lives by providing an industry-leading patient and provider experience.” — Dr. Jonathan Calkwood, Medical Director at Infusion Associates
- “We feel privileged to call the Vivo team our partners seeing first-hand their passionate focus on delivering great clinical outcomes and an industry-leading patient experience.” — Brad Coppens, Senior Partner at InTandem and Member of the Board of Directors at Vivo Infusion
SoHC's Take
The acquisition of Infusion Associates by Vivo Infusion marks a significant step in expanding accessible and affordable ambulatory infusion services across the Midwest and beyond. By integrating Infusion Associates’ unique operating model and extensive clinical expertise, Vivo Infusion is poised to enhance patient care and experience. The substantial financial backing from InTandem Capital Partners further solidifies Vivo’s position to scale its operations and continue its mission of delivering top-notch healthcare services. This strategic move not only broadens Vivo Infusion’s geographical footprint but also strengthens its capacity to manage complex chronic conditions, benefiting a wider patient population.
